{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T18:57:14Z","timestamp":1735585034146},"reference-count":44,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>\n          Zusammenfassung\n        <\/jats:title><jats:p>Die menopausale Hormontherapie (MHT) begann 1942 in den USA und wurde weltweit in den 1960er-Jahren wegen der sehr erfolgreichen Behandlung vegetativer und vasomotorischer Beschwerden sehr popul\u00e4r. Diese manifestieren sich in vielen F\u00e4llen schon pr\u00e4menopausal und k\u00f6nnen \u00fcber ca. 10 Jahre andauern und die Lebensqualit\u00e4t erheblich einschr\u00e4nken. Viele Frauen stellen sich in dieser perimenopausalen Lebensphase nicht prim\u00e4r beim Gyn\u00e4kologen, sondern beim Hausarzt oder Kardiologen vor, da Blutdruckschwankungen und insbesondere die typischen n\u00e4chtlichen Palpitationen Angst machen. Eine fach\u00fcbergreifende Betrachtung kann unn\u00f6tige diagnostische Ma\u00dfnahmen bis zur invasiven Herzkatheteruntersuchung und inad\u00e4quate Therapien mit Betablockern, Antidepressiva und Sedativa vermeiden.<\/jats:p><jats:p>Daneben ist es auch in der haus\u00e4rztlich-internistischen Praxis wichtig, die Auswirkungen sowohl eines Hormonmangels als auch einer Hormontherapie auf innere Organerkrankungen zu kennen. Die Hormontherapie kann vorbestehende Erkrankungen positiv, negativ oder gar nicht beeinflussen. Betroffene Patientinnen erwarten zurecht eine enge Kooperation der\u00a0Spezialisten \u2013 Gyn\u00e4kologen, Endokrinologen und Internisten \u2013, wenn es um die Entscheidung f\u00fcr oder gegen eine menopausale Hormontherapie (MHT) geht, insbesondere nach den Unsicherheiten, welche die mittlerweile revidierten Ergebnisse der WHI (women\u2019s health initiative) -Studie hervorgerufen hatten.<\/jats:p>","DOI":"10.1055\/a-1180-3127","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T23:36:12Z","timestamp":1609803372000},"page":"41-47","source":"Crossref","is-referenced-by-count":1,"title":["Die menopausale Hormontherapie aus internistisch endokrinologischer Sicht"],"prefix":"10.1055","volume":"146","author":[{"given":"Roland","family":"G\u00e4rtner","sequence":"additional","affiliation":[{"name":"Medizinische Klinik Innenstadt der LMU, M\u00fcnchen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Albrich","sequence":"additional","affiliation":[{"name":"Frauen\u00e4rzte f\u00fcnf H\u00f6fe, M\u00fcnchen"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3390\/medicina55090602","article-title":"The controversial history of hormone replacement threrapy","volume":"55","author":"A Cagnacci","year":"2019","journal-title":"Medicina"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"The women\u2019s health initiative hormone therapy trials: update and overview of the health outcomes during the intervention and post-stopping phase","volume":"310","author":"J E Manson","year":"2013","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Writing Group for the Women\u2019s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"J E Rossouw","year":"2002","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Women\u2019s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women\u2019s Health Initiative randomized controlled trial","volume":"291","author":"G L Anderson","year":"2004","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1001\/jama.2017.11217","article-title":"WHI Investigators. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women\u2019s Health Initiative Randomized Trials","volume":"318","author":"J E Manson","year":"2017","journal-title":"JAMA"},{"key":"ref6","first-page":"e6409","article-title":"Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial","volume":"345","author":"L L Schierbeck","journal-title":"BMJ 2012 Sept"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1210\/jc.2015-2236","article-title":"Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline","volume":"100","author":"C A Stuenkel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13697137.2015.1129166","article-title":"IMS Writing Group. 2016 IMS Recommendations on women\u2019s midlife health and menopause hormone therapy","volume":"19","author":"R J Baber","year":"2016","journal-title":"Climacteric"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/GME.0000000000000921","article-title":"The 2017 hormone therapy position statement of The North American Menopause Society","volume":"24","author":"The NAMS 2017 Hormone Therapy Position Statement Advisory Panel","year":"2017","journal-title":"Menopause"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-007-9523-x","article-title":"Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study","volume":"107","author":"A Fournier","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ncpcardio1234","article-title":"Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity?","volume":"5","author":"R K Hermsmeyer","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13697137.2018.1439915","article-title":"Menopausal hormone therapy: a better and safer future","author":"D A Davey","year":"2018","journal-title":"Climacteric"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMp1514242","article-title":"Menopause Management \u2013 Getting Clinical Care Back on Track","volume":"374","author":"J E Manson","year":"2016","journal-title":"N Engl J Med"},{"key":"ref14","first-page":"CD01407","article-title":"Bioidentical hormones for women with vasomotor symptoms","volume":"8","author":"A M Gaudard","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1001\/jamainternmed.2014.8063","article-title":"Study of Women\u2019s Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition","volume":"175","author":"N E Avis","year":"2015","journal-title":"JAMA Intern Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/GME.0000000000001126","article-title":"Vasomotor symptoms in women over 60: results from the Data Registry on Experiences of Aging, Menopause, and Sexuality (DREAMS)","volume":"25","author":"P S David","year":"2018","journal-title":"Menopause"},{"key":"ref17","first-page":"351","article-title":"A prospective population-based study of menopausal symptoms","volume":"96","author":"L Dennerstein","year":"2000","journal-title":"Obstet Gynecol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/GME.0000000000000485","article-title":"Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel","volume":"23","author":"S Caruso","year":"2016","journal-title":"Menopause"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/GME.0000000000000450","article-title":"Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality","volume":"22","author":"T S Mikkola","year":"2015","journal-title":"Menopause"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMp038161","article-title":"Unstable coronary-artery plaques","volume":"349","author":"D D Heistad","year":"2003","journal-title":"N Engl J Med"},{"key":"ref21","first-page":"123","article-title":"A systemic review and meta-analysis to examine the \u201ctiming hypothesis\u201dof hormone replacement thererapy on mortality, coronary heart disease, and stroke","volume":"22","author":"M Nudy","year":"2019","journal-title":"Int J Cardiol Heart Vasc"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.fertnstert.2007.07.1298","article-title":"Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review","volume":"90","author":"M Hemelaar","year":"2008","journal-title":"Fertil Steril"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1161\/hc4401.98414","article-title":"Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women","volume":"104","author":"M G Shlipak","year":"2001","journal-title":"Circulation"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.maturitas.2016.09.015","article-title":"Decreased mortality risk due to first acute coronary syndrome in women with postmenopausal hormone therapy use","volume":"94","author":"P Tuomikoski","year":"2016","journal-title":"Maturitas"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/gme.0b013e31824d8f40","article-title":"Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging","volume":"19","author":"S D Harlow","year":"2012","journal-title":"Menopause"},{"key":"ref26","first-page":"745","article-title":"Modification of blood pressure in postmenopausal women: role of hormone replacement therapy","volume":"11","author":"M Cannoletta","year":"2014","journal-title":"Int J Womens Health"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000095726","article-title":"Hormonersatztherapie bei internistischen Risikopatientinnen","volume":"46","author":"A O Mueck","year":"2006","journal-title":"Gynakol Geburtshilfliche Rundsch"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12944-017-0612-5","article-title":"The effects of progersteron on blood lipids in hormone replacement therapy","volume":"16","author":"Y Jiang","year":"2017","journal-title":"Lipids in Health and disease"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"c2519","DOI":"10.1136\/bmj.c2519","article-title":"Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study","volume":"340","author":"C Renoux","year":"2010","journal-title":"BMJ"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1210\/er.2016-1146","article-title":"Menopausal hormone therapy and Type 2 diabetes prevention: Evidence, mechanisms, and clinical implications","volume":"38","author":"F Mauvais-Jarvis","year":"2017","journal-title":"Endocrine Reviews"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1210\/jc.2012-1410","article-title":"Vasomotor symptoms and insulin resistance in the study of women\u2019s health across the nation","volume":"97","author":"R C Thurston","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.2337\/dc12-1020","article-title":"Age at menopause, reproductive life span, and type 2 diabetes risk: results from the EPIC-InterAct study","volume":"36","author":"J S Brand","year":"2013","journal-title":"Diabetes Care"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2337\/dc13-1986","article-title":"Bilateral oophorectomy and the risk of incident diabetes in postmenopausal women","volume":"37","author":"D Appiah","year":"2014","journal-title":"Diabetes Care"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3389\/fimmu.2018.01332","article-title":"Glucocorticoids, Sex Hormones and Immunity","volume":"9","author":"O Bereshchenko","year":"2018","journal-title":"Front Immunol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2741\/e190","article-title":"Changes in the immune system during menopause and aging","volume":"2","author":"C Gameiro","year":"2010","journal-title":"Front Biosci"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jsbmb.2013.09.003","article-title":"The immune system in the menopause: Pros and Cons of hormone therapy","volume":"142","author":"M Ghosh","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"509764","DOI":"10.1155\/2013\/509764","article-title":"Autoimmune thyroid disorders","volume":"2013","author":"M A Iddah","year":"2013","journal-title":"ISRN Endocrinology"},{"key":"ref38","first-page":"63","article-title":"High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome","volume":"150","author":"O E Janssen","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"ref39","first-page":"CD008613","article-title":"Hormone replacement therapy for women with type 1 diabetes mellitus","volume":"6","author":"L Mackay","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/rheumatology\/kex239","article-title":"The role of female hormonal factors in the development of rheumatoid arthritis","volume":"56","author":"D Alp\u00edzar-Rodr\u00edguez","year":"2017","journal-title":"Rheumatology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.clinthera.2014.07.021","article-title":"Estrogen in cardiovascular disease during systemic lupus erythematosus","volume":"36","author":"E L Gilbert","year":"2014","journal-title":"Clin Therapeutics"},{"issue":"11","key":"ref42","doi-asserted-by":"crossref","first-page":"e78016","DOI":"10.1371\/journal.pone.0078016","article-title":"Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France","volume":"8","author":"E Cordina-Duverger","year":"2013","journal-title":"PLoS One"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1200\/JCO.2008.21.6432","article-title":"Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?","volume":"27","author":"A Fournier","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/GME.0000000000000698","article-title":"Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: a Finnish nationwide comparative study","volume":"23","author":"T S Mikkola","year":"2016","journal-title":"Menopause"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1180-3127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T23:37:17Z","timestamp":1609803437000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1180-3127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":44,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2021,1,4]]},"published-print":{"date-parts":[[2021,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1180-3127","relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}